Nurix Therapeutics, Inc.
NRIXNurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of targeted protein degradation medicines for cancer and inflammatory diseases.
Earnings
Q3 2026 report
October 12, 2026Next report
Jan 27, 2027 (in 3 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of targeted protein degradation medicines for cancer and inflammatory diseases. The company utilizes a proprietary AI-integrated discovery engine and E3 ligase expertise to create small molecules and degrader antibody conjugates that modulate protein levels. Their platform aims to address previously undruggable targets by leveraging DNA-encoded libraries and machine learning to accelerate drug design.
A leader in the targeted protein degradation space with a specialized AI-driven DNA-encoded library (DEL) platform and a robust pipeline of first-in-class candidates.
FAQ
- What is Nurix Therapeutics, Inc.'s market cap?
- Nurix Therapeutics, Inc. (NRIX) has a market capitalization of $3.0B and trades on NASDAQ.
- What is Nurix Therapeutics, Inc.'s revenue and profitability?
- Nurix Therapeutics, Inc. generated $701.9M in trailing twelve-month revenue with net income of $294.9M, representing a net margin of 42.0%, with free cash flow of $369.8M. The latest reported period is Q3 2026.
- Who are Nurix Therapeutics, Inc.'s competitors?
- Nurix Therapeutics, Inc.'s key competitors include Kymera Therapeutics, Inc., Arvinas, Inc., C4 Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Nurix Therapeutics, Inc. partner with?
- Nurix Therapeutics, Inc.'s notable partners include Gilead Sciences, Inc., Sanofi S.A., Pfizer Inc..
- Where is Nurix Therapeutics, Inc. headquartered?
- Nurix Therapeutics, Inc. is headquartered in United States of America and employs approximately 284 people. It has been publicly traded since 2020.
